Redcare Pharmacy Braces for Bundesrat Verdict After Blistering Q1 Prescription Growth
Published on 05/28/2026 at 15:24 | Redaktion boerse-global.de
The next few weeks could define the trajectory of Redcare Pharmacy’s stock. Germany’s Bundesrat is due to rule on the Apothekenversorgung-Weiterentwicklungsgesetz, the pharmacy reform package that cleared the Bundestag on May 22, 2026. For the online pharmacy operator, the outcome is a double-edged sword: easier access to prescription drugs could turbocharge an already accelerating e?prescription business, but parallel rules tightening the logistics of mail?order medicines risk inflating costs just as management tries to steer the international division toward breakeven.
Redcare’s first?quarter numbers, shared at the dbAccess European Champions Conference in Frankfurt this week, provide the operational backdrop. Revenue climbed to €849.5 million from €717.3 million a year earlier, and the adjusted EBITDA margin improved to 1.7% from a much lower base, with absolute adjusted EBITDA jumping 58% to €14.4 million. The net loss narrowed marginally to €10.5 million from €10.8 million. Crucially, the full?year guidance remains intact: group revenue growth of 13?15% and an adjusted EBITDA margin of at least 2.5%.
Prescription engine firing on all cylinders
The most explosive figure came from the German prescription (Rx) segment, where sales surged 55% in the first quarter. Adoption of the electronic prescription is the primary driver: the net promoter score for the e?prescription process jumped to 76 from 58 a year earlier, reflecting smoother digital workflows. In the non?prescription (non?Rx) market, growth accelerated to 9% from 5% in the prior quarter, with early April data hinting at a further pickup to 11%.
Redcare now commands 67% of Germany’s online prescription market, a dominant share that positions it to capture a large slice of any incremental Rx volume from the reform. Yet the wider German pharmacy landscape continues to shrink – only 16,541 outlets were operating at the end of March 2026, down from 16,601 at the close of 2025 and roughly 20% fewer than in 2013. Each closure pushes more prescription volume toward digital channels.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
International costs and margin pressure
The international segment, covering seven markets including France, Belgium, Italy and the Netherlands, remains the financial drag. Redcare is targeting break?even on an adjusted EBITDA basis for the unit by 2026, but the path is proving capital?intensive. A new logistics hub in Pilsen, Czech Republic, will add capacity for 15 million packages annually, and management has already trimmed its medium?term margin ambition from above 8% to over 5%. For this year, the goal is a group adjusted EBITDA margin of at least 2.5%, a level that leaves little room for error if regulatory costs escalate.
The group’s gross margin eased to 21.0% from 23.3% a year ago, though it held steady against the fourth quarter of 2025. Cash at the end of March stood at €135 million, even after the repayment of €64.5 million in convertible bonds. The active customer base grew to 14.2 million, up 1.1 million year?on?year, with roughly 90% of orders representing repeat purchases.
Analyst optimism restrained by share price reality
Despite the operational momentum, the stock remains under severe pressure. At the conference the shares were quoted at €44.08, some 63% below the 52?week high of €119.50, though they have recovered 42% from the March trough of €31. The year?to?date loss stands at 33.9%, and the stock trades a significant 27.5% below its 200?day moving average.
Redcare Pharmacy at a turning point? This analysis reveals what investors need to know now.
Analysts, however, are not giving up. The consensus price target hovers around €90, with Deutsche Bank among the more bullish, pegging fair value at €99. The reform, if it delivers a net positive for digital pharmacy, is seen as a potential catalyst for re?rating. But that depends on the fine print for mail?order regulation – earlier drafts imposed stricter documentation, contract and temperature?control requirements that would hit costs directly.
The next key date for Redcare is the half?year report on July 29, 2026. By then the Bundesrat will have spoken, and investors will have a clearer picture of whether the political winds are blowing the company’s way or adding fresh headwinds to an already delicate margin equation.
Ad
Redcare Pharmacy Stock: New Analysis - 28 May
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
